Green bio specialist company Genolution announced that it participated in 'MEDICA 2025', an international medical device and bio-diagnostic exhibition held in Düsseldorf, Germany from November 17th to 20th.
This exhibition, which is expected to attract approximately 86,000 global buyers and medical and research professionals, will feature approximately 3,000 companies from over 70 countries and showcase the latest medical devices and digital healthcare solutions.
At the exhibition, Genolution showcased its technological competitiveness centered on automated nucleic acid extraction equipment and exosome and cfDNA-based analysis solutions. In particular, it unveiled its new product, NX-Exo, for the first time along with the NX-Jr and NX-Duo Geno-N equipment. Developed for the liquid biopsy and research/clinical EV (extracellular vesicles) analysis markets, NX-Exo supports large-volume sample input and can secure high yields even from samples with scant EVs, such as plasma and serum. It can automatically extract miRNA, DNA, and protein within 40-50 minutes, and its prefilled single cartridge method minimizes reagent preparation, reduces waste, and provides a HAPs (High-Abundant Proteins) removal function.
A Genolution official stated, “NX-Exo is an innovative device that significantly improves speed, purity, and automation suitability compared to existing UC, PEG, and DG methods.” They added, “Through our participation in MEDICA 2025, we will expand our brand awareness in the European and global in vitro diagnostic (IVD)/EV market and seek out new customers and research institutions.”
- See more related articles
You must be logged in to post a comment.